Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (NCT03821935)
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group, PA /ID# 218942 — Springdale, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (64 Sites)
Showing the first 25 of 64 sites.
- Highlands Oncology Group, PA /ID# 218942 — Springdale, Arkansas
- City of Hope National Medical Center /ID# 265620 — Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center /ID# 270785 — Irvine, California
- Yale University School of Medicine /ID# 208356 — New Haven, Connecticut
- AdventHealth Celebration /ID# 224860 — Celebration, Florida
- Duplicate_AdventHealth Cancer Institute - Orlando /ID# 226953 — Orlando, Florida
- Indiana Univ School Medicine /ID# 208384 — Indianapolis, Indiana
- Community Health Network, Inc. /ID# 257032 — Indianapolis, Indiana
- Univ Michigan Med Ctr /ID# 221129 — Ann Arbor, Michigan
- Washington University-School of Medicine /ID# 259684 — St Louis, Missouri
- Intermountain Health West End Clinic Gynecologic Oncology /ID# 266171 — Billings, Montana
- NYU Langone Medical Center /ID# 209822 — New York, New York
- Icahn School of Medicine at Mount Sinai /ID# 264653 — New York, New York
- Carolina BioOncology Institute /ID# 208358 — Huntersville, North Carolina
- The Ohio State University - The James /ID# 217611 — Columbus, Ohio
- Ou Health - Stephenson Cancer Center /ID# 268826 — Oklahoma City, Oklahoma
- Sarah Cannon Research Institute (SMO/Network/Consortium) /ID# 264900 — Nashville, Tennessee
- Renovatio clinical /ID# 265109 — El Paso, Texas
- NEXT Oncology /ID# 208930 — San Antonio, Texas
- Renovatio Clinical /ID# 265054 — The Woodlands, Texas
- University of Washington Medical Center /ID# 268854 — Seattle, Washington
- Chris O'Brien Lifehouse /ID# 213236 — Camperdown, New South Wales
- Icon Cancer Centre /ID# 224961 — South Brisbane, Queensland
- Cliniques Universitaires UCL Saint-Luc /ID# 218466 — Brussels, Brussels Capital
- University Health Network_Princess Margaret Cancer Centre /ID# 209423 — Toronto, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumors Cancer
- A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors — Scottsdale, Arizona
- Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors — Boston, Massachusetts
- A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors — Los Angeles, California
- A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. — Los Angeles, California
- ORB-021 In Patients With Advanced Solid Tumors — Scottsdale, Arizona
Explore by condition: All Advanced Solid Tumors Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.